drugset
drugset / Trial / NCT03827798

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa

NCT03827798 ↗

Phase 2 Active not recruiting 248 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The main purpose of this study is to assess preliminary efficacy and safety of CFZ533/iscalimab (Cohort A), LYS006 (Cohort B), MAS825 (Cohort C), LOU064/remibrutinib (Cohort D) and VAY736/ianalumab (Cohort E) in patients with moderate to severe hidradenitis suppurativa and to determine if CFZ533, LYS006, MAS825, LOU064 and VAY736 have an adequate clinical profile for further clinical development.

Timeline

Start
2019-02-27
Primary completion
2024-12-04
Completion
2026-12-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Ianalumab Monoclonal antibody 300 mg Subcutaneous
Subject LYS006 Unknown 20 mg Oral
Subject MAS825 Monoclonal antibody 300 mg Subcutaneous
Subject Remibrutinib Small molecule 25 mg Oral
Subject Remibrutinib Small molecule 100 mg Oral
Subject iscalimab Monoclonal antibody 600 mg Subcutaneous

Indications

hidradenitis suppurativa